Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is one of the 11 Best Short-Term Stocks to Invest in.

A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks’ performance.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company’s lead product, DANYELZA® (naxitamab-gqgk), is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Operating from New Jersey, the company also advances a robust pipeline of investigational cancer therapies.

On August 5, 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in an all-cash transaction valued at approximately $412 million. SERB will commence a tender offer to purchase all outstanding shares of the company’s common stock for $8.60 per share in cash. This offer represents an approximate 105% premium to Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’ closing share price on August 4, 2025, the last full trading day before the transaction announcement.

The acquisition includes DANYELZA, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’ lead commercial oncology asset. SERB intends to use it for broadening its existing Rare Oncology portfolio and expanding its investment in the U.S. market.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price soared by 71.43% this week, gaining a dramatic rebound after a 26.80% yearly drop, making it one of the best short-term biotech investments.

While we acknowledge the potential of YMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.